Trodelvy 180 mg Injection | Indian Pharma Network Trodelvy: Injection for intravenous infusion The FDA approved medicine Trodelvy contains Sacituzumab govitecan-hziy that is used to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This medicine is supplied in 180 mg lyophilized powder in single-dose vials to administer intravenously. The active ingredient in the vials is Sacituzumab govitecan-hziy with inactive ingredients 2-(N-morpholino) ethane sulfonic acid (MES), polysorbate 80 and trehalose dihydrate. One should not substitute Trodelvy for or use with other drugs containing irinotecan or its active metabolite SN-38.
One can readily purchase Trodelvy 180 mg injection readily from certified generic medicine suppliers in India. Indian Pharma Network is one of the WHOGDP certified pharmaceutical suppliers, supplying quality medicines for more than 8 years.
Trodelvy: Dosage and Schedule The medicine Trodelvy contains Sacituzumab govitecan-hziy is used to treat patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Trodelvy comes in the form of single-use vials in 180 mg to administer intravenously. The recommended dose of Trodelvy is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. One should continue treatment until disease progression or unacceptable toxicity and should not administer Trodelvy injection at doses greater than 10 mg/kg.
One should administer Trodelvy as an intravenous infusion only and should not administer as an intravenous push or bolus. In the first infusion one should administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions. In case of subsequent infusions one should administer infusion over 1 to 2 hours if prior infusions were tolerated and observe patients during the infusion and for at least 30 minutes after infusion. Healthcare professionals recommend prior to each dose of Sacituzumab govitecan 180 mg, premedication for prevention of infusion reactions and prevention of chemotherapy induced nausea and vomiting (CINV).
TRODELVY FDA APPROVAL:FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer Source - https://helpforheallth.blogspot.com/2022/11/trodelvy-180-mg-injection-price-inindia.html